GlaxoSmithKline PLC (GSK.L)
28 Apr 2017
* Q1 group loss before tax of 8.3 million naira versus profit of 167.5 million naira year ago
* Q1 adjusted EPS 25.0 pence vs consensus 24.5p (Adds analyst comment, latest shares)
LONDON GlaxoSmithKline's new chief executive reported slightly better than expected first-quarter results on Wednesday, keeping the drugmaker on track to hit financial targets in 2017 as it braces for generic competition to blockbuster lung drug Advair.
Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair.
April 20 Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair.
April 20 Teva Pharmaceutical Industries Ltd launched its asthma inhaler and the authorized generic of the drug on Thursday, nearly three months after it got U.S. approval to market a copy of GlaxoSmithKline's best-selling Advair.
* JV between GSK, Daiichi Sankyo submitted new drug application in Japan seeking approval for candidate shingles vaccine, shingrix Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)
April 13 Drug company Innoviva Inc said on Thursday it would undertake a review of its costs, including executive compensation following pressure from activist investor Sarissa Capital Management LP.
(In this April 10th story, corrects paragraphs 1 and 11 to drop the words "stem cell")
April 10 OncoMed Pharmaceuticals Inc said it would discontinue a trial testing its experimental therapy demcizumab as an initial treatment for advanced pancreatic cancer, after the addition of the drug to standard-of-care failed a mid-stage study.